Mangoceuticals, Inc. (Nasdaq: MGRX) (“
MangoRx” or
the “Company”), a company focused on developing, marketing, and
selling a variety of men’s health and wellness products via a
secure telemedicine platform, including its uniquely formulated
hair growth product (“GROW”) and erectile dysfunction (“ED”) drug
(“Mango”), announces that regardless of who loses the Big Game this
Sunday, they are prepared to offer a free one-year supply of its
Mango ED products for the entire losing team, ensuring they still
get sacked after the game.
MangoRx is committed to helping men tackle hard
issues. In addition to offering the losing team players the
opportunity to score, fans can also get in on the fun with a
special discount code equal to the game’s point difference, along
with discounts site-wide. This code will be available to fans
following the results of the Big Game.
MangoRx’s advisory board member, Dr. Douglas
Christianson notes, "The sting of defeat, whether in sports or
life, can echo into our intimate lives, as studies link depression
and performance anxiety with erectile dysfunction, illuminating the
profound impact of our emotional health on physical performance in
the bedroom."
MangoRx’s signature ED product Mango (think
"Man, Go) is a uniquely formulated drug which leverages the active
ingredients found in either Cialis™ (Tadalafil) or Viagra™
(Sildenafil). MangoRx’s Tadalafil and Sildenafil based Mango ED
products are compounded with both Oxytocin and L-Arginine in a
tasty Mango-flavored, rapid dissolve tablet (RDT).
“Just because your team doesn’t perform on the
field, doesn’t mean the fans shouldn’t be able to score. We
understand the daily pressures for men that come with everyday life
and the sadness that comes when your team can’t put it through the
goal post. These pressures ultimately affect performance, and our
job is to help the fans avoid any false starts, and make sure you
get it through the uprights every time,” says Jacob Cohen,
Co-Founder and CEO of MangoRx.
MangoRx will also be the marquee sponsor for
several Barstool Sports’ week-long programming surrounding the Big
Game in Las Vegas including The Dozen Trivia Live Show Pro-Am with
Dave Portnoy and other Barstool fan favorites, Stool Scenes' "Super
Bowl Special", and The Rundown, in addition to sponsoring the Big
Game’s Day-of livestream from Chicago HQ, the brand’s content house
in Las Vegas, and several other podcasts and radio shows.
In addition, as a Marquee Sponsor, MangoRx will
be prominently featured on the Barstool Podcasts starting the week
of January 22nd and running through March 15th with an estimated
number of over 7 million views and impressions. MangoRx’s products
and branding will also be present throughout their newly opened
Chicago HQ.
About MangoRx
MangoRx is focused on developing a variety of
men's health and wellness products and services via a secure
telemedicine platform. To date, the Company has identified men's
wellness telemedicine services and products as a growing sector and
especially related to the area of erectile dysfunction (ED) and
hair growth. Interested consumers can use MangoRx’s telemedicine
platform for a smooth medical prescription that is exclusively
compounded for each individual. Orders will then be reviewed by a
physician and, if approved, fulfilled and discreetly shipped
through MangoRx’s partner compounding pharmacy and right to the
patient’s doorstep.
To learn more about MangoRx’s mission and other
products, please visit www.MangoRx.com or on social media
@Mango.Rx.
Cautionary Note Regarding
Forward-Looking Statements
Certain statements made in this press release
contain forward-looking information within the meaning of
applicable securities laws, including within the meaning of the
Private Securities Litigation Reform Act of 1995 ("forward-looking
statements"). These forward-looking statements represent the
Company's current expectations or beliefs concerning future events
and can generally be identified using statements that include words
such as "estimate," "expects," "project," "believe," "anticipate,"
"intend," "plan," "foresee," "forecast," "likely," "will," "target"
or similar words or phrases. These forward-looking statements are
subject to risks, uncertainties and other factors, many of which
are outside of the Company's control which could cause actual
results to differ materially from the results expressed or implied
in the forward-looking statements, including, but not limited to;
our ability to obtain additional funding and generate revenues to
support our operations; risks associated with our ED product which
have not been, and will not be, approved by the U.S. Food and Drug
Administration ("FDA") and have not had the benefit of the FDA's
clinical trial protocol which seeks to prevent the possibility of
serious patient injury and death; risks that the FDA may determine
that the compounding of our planned products does not fall within
the exemption from the Federal Food, Drug, and Cosmetic Act ("FFDCA
Act") provided by Section 503A; risks associated with related party
relationships and agreements; the effect of data security breaches,
malicious code and/or hackers; competition and our ability to
create a well-known brand name; changes in consumer tastes and
preferences; material changes and/or terminations of our
relationships with key parties; significant product returns from
customers, product liability, recalls and litigation associated
with tainted products or products found to cause health issues; our
ability to innovate, expand our offerings and compete against
competitors which may have greater resources; our significant
reliance on related party transactions; the projected size of the
potential market for our technologies and products; risks related
to the fact that our Chairman and Chief Executive Officer, Jacob D.
Cohen and President, Jonathan Arango, combined have majority voting
control over the Company; risks related to the significant number
of shares in the public float, our share volume, the effect of
sales of a significant number of shares in the marketplace, and the
fact that the majority of our shareholders paid less for their
shares than the public offering price of our common stock in our
recent initial public offering; the fact that we have a significant
number of outstanding warrants to purchase shares of common stock
at $1.00 per share, the resale of which underlying shares have been
registered under the Securities Act of 1933, as amended; our
ability to build and maintain our brand; cybersecurity, information
systems and fraud risks and problems with our websites; changes in,
and our compliance with, rules and regulations affecting our
operations, sales, marketing and/or our products; shipping,
production or manufacturing delays; regulations we are required to
comply with in connection with our operations, manufacturing,
labeling and shipping; our dependency on third-parties to prescribe
and compound our ED product; our ability to establish or maintain
relations and/or relationships with third-parties; potential safety
risks associated with our Mango ED product, including the use of
ingredients, combination of such ingredients and the dosages
thereof; the effects of high inflation, increasing interest rates
and economic downturns, including potential recessions, as well as
macroeconomic, geopolitical, health and industry trends, pandemics,
acts of war (including the ongoing Ukraine/Russian conflict) and
other large-scale crises; our ability to protect intellectual
property rights; our ability to attract and retain key personnel to
manage our business effectively; our ability to maintain the
listing of our common stock on the Nasdaq Capital Market; overhang
which may reduce the value of our common stock; volatility in the
trading price of our common stock; and general consumer sentiment
and economic conditions that may affect levels of discretionary
customer purchases of the Company's products, including potential
recessions and global economic slowdowns. Although we believe that
our plans, intentions and expectations reflected in or suggested by
the forward-looking statements we make in this release are
reasonable, we provide no assurance that these plans, intentions or
expectations will be achieved. Consequently, you should not
consider any such list to be a complete set of all potential risks
and uncertainties. More information on potential factors that could
affect the Company's financial results is included from time to
time in the "Cautionary Note Regarding Forward-Looking Statements,"
"Risk Factors" and "Management's Discussion and Analysis of
Financial Condition and Results of Operations" sections of the
Company's filings with the SEC, including the Company’s Quarterly
Report on Form 10-Q for the Quarter ended September 30, 2023. These
filings are available at www.sec.gov and at our website at
https://www.mangoceuticals.com/sec-filings. All subsequent written
and oral forward-looking statements attributable to the Company or
any person acting on behalf of the Company are expressly qualified
in their entirety by the cautionary statements referenced above.
Other unknown or unpredictable factors also could have material
adverse effects on the Company's future results. The
forward-looking statements included in this press release are made
only as of the date hereof. The Company cannot guarantee future
results, levels of activity, performance or achievements.
Accordingly, you should not place undue reliance on these
forward-looking statements. Finally, the Company undertakes no
obligation to update these statements after the date of this
release, except as required by law, and takes no obligation to
update or correct information prepared by third parties that are
not paid for by the Company. If we update one or more
forward-looking statements, no inference should be drawn that we
will make additional updates with respect to those or other
forward-looking statements.
Follow Mangoceuticals and MangoRx on social
media:https://www.instagram.com/mango.rxhttps://twitter.com/Mangoceuticalshttps://www.facebook.com/MangoRxOfficial
FOR PUBLIC RELATIONSLucky Break Public
RelationsSahra SimpsonSahra@luckybreakpr.com(323) 602-0091 ext.
704
Mangoceuticals (NASDAQ:MGRX)
Gráfico Histórico do Ativo
De Ago 2024 até Set 2024
Mangoceuticals (NASDAQ:MGRX)
Gráfico Histórico do Ativo
De Set 2023 até Set 2024